OverviewSuggest Edit
Alector is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
| Type | Public | |
| Founded | 2013 | |
| HQ | South San Francisco, CA, US | Map |
| Website | alector.com | |
| Employee Ratings | More |
Recent NewsAll News
- Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development
- Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
- Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
- Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference
Key People/Management at Alector
Arnon Rosenthal
Robert King
Sabah Oney
Daniel Maslyar
Kristina Vlaovic
Virginia DeJesus-Ruef
Alector Office Locations
Alector Financials and Metrics
Alector Revenue
| USD | |
|---|---|
Revenue (FY, 2020) | 21.1m |
Net income (FY, 2020) | (190.2m) |
EBIT (FY, 2020) | (195.2m) |
Market capitalization (31-Dec-2021) | 1.7b |
Closing stock price (31-Dec-2021) | 20.7 |
Cash (31-Dec-2020) | 50.0m |
EV | 1.7b |
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (8.4m) | (19.6m) | (34.9m) | (18.6m) | (43.1m) | (74.9m) | (40.0m) | (85.3m) |
Depreciation and Amortization | 212.0k | 464.0k | 743.0k | 298.0k | 1.1m | 2.4m | 1.4m | 2.9m |
Accounts Payable | (783.0k) | (830.0k) | (604.0k) | 683.0k | 414.0k | 132.0k | 3.1m | 4.4m |
Cash From Operating Activities | 184.5m | 167.5m | 145.1m | (23.6m) | (41.6m) | (70.5m) | (32.3m) | (78.3m) |
| USD | FY, 2017 |
|---|---|
Financial Leverage | -4.5 x |
Alector Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Alector LLC |
Alector Revenue Breakdown
Alector revenue breakdown by business segment: 100.0% from Collaboration
Alector Cybersecurity Score
Alector Environment, Social & Governance (ESG) Ratings
Alector Online and Social Media Presence
Alector's Trends
Alector News and Updates
Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors
Alector Frequently Asked Questions
When was Alector founded?
Alector was founded in 2013.
Who are Alector key executives?
Alector's key executives are Arnon Rosenthal, Robert King and Sabah Oney.
How many employees does Alector have?
Alector has 126 employees.
What is Alector revenue?
Latest Alector annual revenue is $21.1 m.
What is Alector revenue per employee?
Latest Alector revenue per employee is $167.4 k.
Who are Alector competitors?
Competitors of Alector include ACADIA Pharmaceuticals, Cortexyme and Verge Genomics.
Where is Alector headquarters?
Alector headquarters is located at 131 Oyster Point Blvd #600, South San Francisco.
Where are Alector offices?
Alector has offices in South San Francisco and Milpitas.
How many offices does Alector have?
Alector has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies